Sandoz's Share Price Rises Following Agreement with Shanghai Henlius Biotech

Shanghai Henlius Biotech's share price increased by 1.2% on Monday, reaching 68.1 Hong Kong dollars. This followed the Chinese biotechnology company's announcement of a strategic partnership with Swiss pharmaceutical company Sandoz.

Under the agreement, Sandoz will obtain exclusive rights to register and sell up to 10 Henlius products outside of China. The collaboration covers treatment drugs in oncology, autoimmune diseases, and ophthalmology.

The agreement provides Henlius with the opportunity to expand its activities in international markets. In this process, the company will leverage Sandoz's existing sales network and expertise, which will facilitate the introduction of new products to foreign markets.

Source: Investing.com